Obio Technology (shanghai) Corp Ltd
688238
Company Profile
Business description
Obio Technology (shanghai) Corp Ltd is a biotechnology company focusing on the field of gene therapy, focusing on the development of gene therapy vectors, gene function research, drug targets and efficacy for the basic research of gene therapy Research and other CRO services, and provide CDMO services such as process development and testing, IND-CMC pharmaceutical research, and clinical sample GMP production for the research and development of genetic drugs.
Contact
Lane 908, Ziping Road
Building 19
International Medical Park, Pudong New Area
Shanghai201321
CHNT: +86 2158585887
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
692
Stocks News & Analysis
stocks
Market Minute: RBA cuts rates again, US CPI data released
This week, the RBA cut rates after a surprise hold in July; CBA reported earnings ; US inflation data came out, showing its highest reading since February.
stocks
Is the market still overlooking Alibaba’s AI potential?
Despite a 40% share price rally this year, investors could still be underestimating Alibaba’s cloud growth prospects.
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
A round up of notable stories and reactions as ASX earnings season gathers steam.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,212.10 | 63.00 | 0.69% |
| CAC 40 | 7,924.23 | 53.89 | 0.68% |
| DAX 40 | 24,449.55 | 72.05 | 0.30% |
| Dow JONES (US) | 44,911.26 | 11.01 | -0.02% |
| FTSE 100 | 9,167.20 | 10.04 | -0.11% |
| HKSE | 25,270.07 | 249.25 | -0.98% |
| NASDAQ | 21,710.67 | 2.47 | -0.01% |
| Nikkei 225 | 43,378.31 | 729.05 | 1.71% |
| NZX 50 Index | 12,889.38 | 55.30 | 0.43% |
| S&P 500 | 6,468.54 | 1.96 | 0.03% |
| S&P/ASX 200 | 8,938.60 | 64.80 | 0.73% |
| SSE Composite Index | 3,696.77 | 30.33 | 0.83% |